Bone Metastases News

FDA Grants Priority Review to Frontline Cabozantinib in RCC - OncLive



OncLive
 
FDA Grants Priority Review to Frontline Cabozantinib in RCC 
OncLive
The FDA has granted a priority review to a supplemental new drug application (sNDA) for cabozantinib (Cabometyx) for previously untreated patients with advanced renal cell carcinoma (RCC), according to Exelixis, the developer of the multikinase inhibitor.
Exelixis, Inc. - EXEL - Stock Price Today - Zacks Zacks Investment Research

all 151 news articles » 


Researchers Develop New Strategy to Target Breast Cancer Metastasis in Bones - Breast Cancer News



Breast Cancer News
 
Researchers Develop New Strategy to Target Breast Cancer Metastasis in Bones 
Breast Cancer News
A new method using small particles loaded with chemotherapy drugs is a viable approach to target breast cancer cells that have spread to the bones, according to a report that appeared in the journal Cancer Research. The strategy, developed by a ...

 


PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone ... - UroToday



PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone ... 
UroToday
The majority of patients (97%) presented with bone metastases, 77% with lymph node metastases and 32% with visceral metastases. All patients were treated with at least one line of chemotherapy. Either abiraterone or enzalutamide had been given in 100% ...

 


Radium-223 Plus Anti-VEGF Therapy Reduces Bone Turnover in Advanced RCC - OncLive



OncLive
 
Radium-223 Plus Anti-VEGF Therapy Reduces Bone Turnover in Advanced RCC 
OncLive
Patients with advanced renal cell carcinoma (RCC) with bone metastases had reductions in bone-turnover markers (BTMs) when treated with radium-223 dichloride (Xofigo) and a VEGF inhibitor, although the incidence of symptomatic skeletal events (SSEs) ...

 


Cancer Supportive Care Products Market 2024: R&D Investments By Manufacturers To Innovate Supportive Care ... - Medgadget (blog)



Cancer Supportive Care Products Market 2024: R&D Investments By Manufacturers To Innovate Supportive Care ... 
Medgadget (blog)
On the basis of therapeutic area the market is segmented into oral mucositis and dry mouth, chemotherapy induced nausea and vomiting cancer pain, chemotherapy induced anemia, and chemotherapy induced neutropenia, bone metastases. On the basis of ...

and more » 


Chemo-loaded nanoparticles target breast cancer that has spread to bone - Medical Xpress



Medical Xpress
 
Chemo-loaded nanoparticles target breast cancer that has spread to bone 
Medical Xpress
Seeking new treatments for metastatic breast cancer, researchers have designed nanoparticles (shown in magenta) that carry chemotherapy and are targeted directly to tumors that have spread to bone. The strategy, developed in mouse studies ?more.

 


Nanoparticles improve fight against breast cancer in bone - Futurity: Research News



Futurity: Research News
 
Nanoparticles improve fight against breast cancer in bone 
Futurity: Research News
metastatic breast cancer Seeking new treatments for metastatic breast cancer, researchers have designed nanoparticles (shown in magenta) that carry chemotherapy and are targeted directly to tumors that have spread to bone. The strategy, developed in ...

and more » 


Abiraterone Approaches EU Approval for Newly Diagnosed Hormone-Sensitive Prostate Cancer - OncLive



OncLive
 
Abiraterone Approaches EU Approval for Newly Diagnosed Hormone-Sensitive Prostate Cancer 
OncLive
Abiraterone acetate was administered at 1000 mg daily and prednisone was given at 5 mg daily. Patients had either a positive bone scan or a metastatic lesion at the time of diagnosis on CT or MRI. Patients had not previously received ADT therapy and ...

 


Pivotal Role Remains With Bone-Targeting Agents in mCRPC - OncLive



OncLive
 
Pivotal Role Remains With Bone-Targeting Agents in mCRPC 
OncLive
Ryan: Bone-targeting agents are critically important, and that's because 90% of men who die from prostate cancer die with boney metastases, and often they die because of the complications of boney metastases. While we continue our research and clinical ...

 


Cancer and Your Bones: What You Need to Know - Mountain Grove News Journal



Cancer and Your Bones: What You Need to Know 
Mountain Grove News Journal
Bone mets can cause bones to weaken, leading to fractures, as well as three other types of serious bone problems: a need for surgery to prevent or repair broken bones, a need for radiation treatments to the bone and pressure on the spinal cord (spinal ...

and more »